Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.51
Bid: 3.02
Ask: 4.00
Change: 0.00 (0.00%)
Spread: 0.98 (32.45%)
Open: 3.51
High: 0.00
Low: 0.00
Prev. Close: 3.51
PRM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director Dealing

31 Jul 2008 16:13

For Immediate Release 31 July 2008

PROTEOME SCIENCES plc

("Proteome Sciences" or the "Company")

PRESS RELEASE

DIRECTORS' SHAREHOLDINGS

Proteome Sciences announces that on 31 July 2008 it granted a conditional award of 1,882,500 Ordinary Shares of 1p each in the Company ("Ordinary Shares") to C.D.J. Pearce, Chief Executive and of 1,170,000 Ordinary Shares of 1p each to J.L. Malthouse, Finance Director, under its Long-Term Incentive Plan ("LTIP") based on a closing mid-market price on 30 July 2008 of 20p per Ordinary Share.

In accordance with the rules of the LTIP, the Ordinary Shares awarded will vest 3 years after the date of grant subject to the Company achieving a target total shareholder return (TSR) over a three-year performance period relative to the AIM Healthcare Index at the start of that period. TSR is the aggregate of share price growth and the value of dividend payments during the performance period. No shares will be released unless the Company's TSR performance exceeds that of the index, in which case 30% of the award will vest with full vesting only if the Company's TSR performance exceeds that of the Index by 10%, with a pro-rata award between 30% and 100% for each percentage point of out-performance up to 10%.

The Remuneration Committee of the Board of Directors believes that today's award under the LTIP aligns the interests of shareholders with those of the executive by making the award dependent on the success of management in delivering superior returns to shareholders.

C.D.J. Pearce currently holds 6,538,075 shares in the Company, and has a previous conditional award under the LTIP of up to 504,523 shares.

J.L. Malthouse currently holds 625,000 shares in the Company, and has a previous conditional award under the LTIP of up to 470,352 shares.

Ends

Proteome Sciences plc

Christopher Pearce James Malthouse

Chief Executive Officer Finance Director

christopher.pearce@proteomics.com james.malthouse@proteomics.com

Tel: +44 (0)1932 865065

Nominated Adviser

Landsbanki Securities (UK) Limited

Shaun Dobson / Claes SpĴng Tel: +44 (0)20 7426 9000

vendor
Date   Source Headline
26th Apr 20247:00 amRNSContract Win
10th Apr 20247:00 amRNSFinal Results
2nd Jan 20247:00 amRNSCompletion of new facility in San Diego
30th Nov 20237:00 amRNSTrading Update
2nd Oct 20237:00 amRNSLaunch of Single Cell Proteomics Services
30th Aug 20232:14 pmRNSInvestor Presentation
25th Aug 20237:00 amRNSInterim Results
1st Jun 20239:43 amRNSRepayment of Loan
17th May 20231:05 pmRNSResult of AGM
17th May 20237:00 amRNSAGM Statement
12th May 20237:00 amRNSExpansion into the US
14th Apr 202310:45 amRNSDirector/PDMR Shareholding
6th Apr 202311:34 amRNSDirector/PDMR Shareholding
6th Apr 202310:30 amRNSInvestor Presentation
4th Apr 20237:00 amRNSFinal Results
29th Mar 20237:00 amRNSNotice of Results
6th Mar 20234:35 pmRNSPrice Monitoring Extension
20th Feb 20237:00 amRNSTrading Update
5th Jan 20237:00 amRNSMilestone Payment for TMT®/TMTpro™ Sales
1st Dec 20224:38 pmRNSGrant of Options and PDMR/director shareholdings
12th Oct 20227:00 amRNSGrant of Options and PDMR/director shareholdings
4th Oct 20227:00 amRNSChange of Auditor
20th Sep 20224:40 pmRNSSecond Price Monitoring Extn
20th Sep 20224:35 pmRNSPrice Monitoring Extension
18th Aug 20227:00 amRNSAppointment of Chief Financial Officer
11th Aug 20227:00 amRNSInvestor Presentation
4th Aug 20227:00 amRNSInterim Results
3rd Aug 20227:00 amRNSMilestone towards Single Cell Proteomics services
26th May 20229:04 amRNSChange of Registered Office
16th May 20221:24 pmRNSResult of AGM
16th May 20227:00 amRNSAGM Statement
12th May 20227:00 amRNSSubstantial Contract Win
26th Apr 20224:45 pmRNSDirector/PDMR Shareholding
21st Apr 20225:13 pmRNSDirector/PDMR Shareholding
11th Apr 20227:00 amRNSInvestor Presentation
1st Apr 20226:01 pmRNSDirector shareholding
31st Mar 20227:09 amRNSFinal Results
30th Mar 202211:24 amRNSLoan amendment
29th Mar 20227:00 amRNSNotice of Results
16th Feb 20224:40 pmRNSSecond Price Monitoring Extn
16th Feb 20224:35 pmRNSPrice Monitoring Extension
3rd Feb 20227:00 amRNSTrading Update
31st Dec 202112:36 pmRNSPrice Monitoring Extension
20th Dec 20217:00 amRNSSubstantial Contract Win
9th Dec 20214:41 pmRNSSecond Price Monitoring Extn
9th Dec 20214:36 pmRNSPrice Monitoring Extension
29th Nov 20214:36 pmRNSPrice Monitoring Extension
26th Nov 20214:36 pmRNSPrice Monitoring Extension
5th Nov 20217:00 amRNSPRM,INmune Bio presenting biomarker discovery data
3rd Nov 20214:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.